Health Headlines: COVID Inquiry, CBD Access, and Opioid Sentencing
A comprehensive summary of recent health news highlights The Lancet's refusal to assist a U.S. Senate COVID-19 inquiry, calls for legal updates on cannabidiol access, Purdue Pharma penalization delays, and advancements in Medicare device coverage. Additionally, news includes initiatives to streamline authorization requirements and developments in the U.S. marijuana industry.
The Lancet, a prominent medical journal, announced it would not comply with a U.S. Senate inquiry into the origins of the COVID-19 pandemic. Richard Horton, the editor-in-chief, revealed this decision during an event in Barcelona, emphasizing the journal's position on the matter.
In legislative developments, former U.S. President Donald Trump urged Congress to modernize laws ensuring access to cannabidiol (CBD) products, advocating for comprehensive availability of such substances to the public.
Meanwhile, Purdue Pharma faces a delay in sentencing for its role in the opioid crisis, as a federal judge allowed further public engagement in the legal proceedings. Such delays illustrate the complex and ongoing challenges surrounding healthcare and regulatory accountability.
(With inputs from agencies.)
ALSO READ
High-Profile Murder Trial of Health Insurance CEO's Alleged Assassin Faces Evidence Challenges
Supreme Showdown: Pharma Giants vs. Medicare Price Plans
Liberty Mutual Expands Stake in Liberty General Insurance to 74%
IndusInd Nippon Life Insurance Sees Financial Growth with Surge in New Business Premium
Liberty Mutual Expands Influence in India's Insurance Sector
Google News